Carenity, part of the EvidentIQ Group, announces change in leadership

Carenity, a prominent patient-centric company and member of the EvidentIQ Group, announces a change in its leadership.

Michael Chekroun, founder of Carenity and outgoing President, will be stepping down from his role as of today. Lise Radoszycki, former COO, will be taking the helm as the new President, bringing extensive experience and expertise that will propel the company into its next phase of expansion and development.

Michael Chekroun has played for the past 12 years a central role in building and shaping the company, leading it through successful initiatives, strategic partnerships, and most of all creating a sustainable and innovative model that allows patients to share their experiences while making medical knowledge advance. Michael has chosen to step down, two years after selling his company to EvidentIQ, to focus on new entrepreneurial projects.

Lise Radoszycki, with a proven track record of success, brings 8 years of experience and a strong vision for Carenity’s future. With a background in data science and biostatistics engineering and having previously occupied crucial leadership roles within the organization, Lise has demonstrated a remarkable ability to effectively implement strategic initiatives and nurture innovation. With her profound industry insights, and exceptional leadership capabilities, Lise is poised to guide Carenity on its continued growth trajectory and ensure that the needs and expectations of patients are better considered by health actors.

Commenting on the leadership transition, Michael said “I am leaving with gratitude and a sense of achievement. I have the conviction that Lise and the team will pursue Carenity’s mission with determination and passion.” 

Lise expressed her enthusiasm about her new role, stating “I am very honored to be given this opportunity, because this company and its patient-centered values are very important to me. I am committed to driving Carenity’s growth by prioritizing the patients’ needs in all my decisions, as well as ensuring our clients’ satisfaction by conducting sophisticated RWE studies.”  

The board of investors and the entire EvidentIQ team extend their sincere appreciation to Michael for his exceptional leadership, dedication, and numerous contributions. They are confident that Lise will build upon the strong foundation laid by Michael and drive Carenity to even greater success.  

About Carenity

Carenity, part of the EvidentIQ Group, is a leading digital CRO specialized in direct-to-patient studies conducted via its digital social platform supporting +500k patients and caregivers worldwide across 1,200+ illnesses.
Since 2011, Carenity’s mission has been to empower patients so they can share their experience with other patients, find information, manage their illness, and generate real-world online research studies.
With its innovative platform, Carenity – the Patient Insights Company – delivers timely and compliant direct-to-patient research solutions to the life sciences industry that fuel the development of better medicines and health services.